Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
Madrigal Pharmaceuticals licensed Arrowhead’s clinical-stage siRNA asset ARO-PNPLA3, targeting the PNPLA3 genetic driver of MASH, via an exclusive global agreement. Phase 1 data showed a 46% reduction in liver fat in homozygous patients, with Madrigal planning combination studies with its flagship drug Rezdiffra.
Key figures
- Drug Name
- ARO-PNPLA3
- Deal Value Usd
- 25000000
- Phase Of Trial
- Phase 1
- Potential milestones usd
- 975000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.